Significance of functional hepatic resection rate calculated using 3D CT/99mTc-galactosyl human serum albumin single-photon emission computed tomography fusion imaging

Table 1 Baseline characteristics of patients (n = 57) n (%)

Age mean (range)	65.7 (34-82)
Men/women	33/24
HBsAg positivity	10 (1.6)
HCV positivity	7 (1.2)
Diagnosis
HCC	26 (45.6)
Hilar cholangiocarcinoma	12 (21.1)
Intrahepatic cholangiocarcinoma	6 (10.5)
Metastatic tumor	4 (7.0)
Hemangioma	4 (7.0)
Others	5 (8.8)
Child-Pugh score (5/6/7/8)	44/8/3/2
Child-Pugh classification (A/B)	52/5
ICGR15, mean (range)	10.8 (1.5-44.3)
LHL15, mean (range)	0.920 (0.712-0.973)
Preoperative therapies	18 (31.6)
TACE	6 (10.5)
Radiation	5 (8.8)
RFA	3 (5.3)
Partial resection	3 (5.3)
Chemotherapy	1 (1.8)
Tumor size > 1000 mL	5 (8.8)
Portal vein thrombosis	8 (14.0)
Hepatic vein thrombosis	3 (5.3)
Preoperative biliary drainage	15 (26.3)
Preoperative portal vein embolization	13 (22.8)

HCC: Hepatocellular carcinoma; ICGR₁₅: Indocyanine green retention at 15 min; LHL₁₅: The hepatic uptake ratio to the liver plus heart at 15 min of ^99mTc-galactosyl human serum albumin; TACE: Transcatheter arterial chemoembolization; RFA: Radiofrequency ablation.

Table 2 Surgical outcomes n (%)

Hepatectomy procedure
Right trisectionectomy	5 (8.8)
Extended right hepatectomy	2 (3.5)
Right hepatectomy ± segment I	18 (31.6)
Central bisectionectomy	5 (8.8)
Left hepatectomy ± segment I	16 (28.1)
Extended left hepatectomy ± segment I	9 (15.8)
Left trisectionectomy ± segment I	2 (3.5)
Biliary reconstruction	15 (26.3)
Surgical duration (min), mean ± SD	432 ± 167
Blood loss, median (g), range	430 (0-5700)
Red blood cell transfusion	18 (31.6)
Postoperative hyperbilirubinemia	6 (10.5)
(T-bil ≥ 5.0 mg/dL)
PHLF ISGLS grade (A/B/C)	9/2/1
Major morbidity (Clavien-Dindo grade ≥ 3)	12/5
(IIIa/IIIb)
Surgery-related death	0

T-bil: Serum total bilirubin, PHLF: Posthepatectomy liver failure, ISGLS: International Study Group of Liver Surgery.